BRAF and melanoma: To model targeted therapy‐induced regression, the establishment of drug‐tolerant residual disease, drug resistance and tumor re‐growth, we transplanted Braf‐mutant murine melanoma cells (YUMM1.7) subcutaneously into C57BL/6J mice.